Advertisement

Pregnancy-Associated Plasma Protein-A Elevation in Patients With Acute Coronary Syndrome and Subsequent Atorvastatin Therapy

      Pregnancy-associated plasma protein-A (PAPP-A) was associated with atherosclerotic plaque vulnerability, whereas statin therapy was associated with increased plaque stability. Eighty-six patients presenting with clinical indications (non–ST-elevation myocardial infarction, unstable angina, and stable angina) for invasive coronary angiography and subsequent verified coronary artery disease (CAD) were randomly assigned in a double-blind manner to atorvastatin 10 or 80 mg/day. PAPP-A, high-sensitivity C-reactive protein (hs-CRP), and lipids were measured at baseline (before statin therapy) and at 1 and 6 months. PAPP-A was significantly increased in 35 patients with acute coronary syndrome (ACS) compared with 51 patients with stable CAD (p <0.001). Patients randomly assigned to atorvastatin 10 mg did not show a significant decrease in PAPP-A from baseline at 1 or 6 months. Patients treated with atorvastatin 80 mg showed a significant decrease at 1 month compared with baseline, but not at 6 months. hs-CRP was not significantly different between the ACS and stable CAD groups. Patients receiving atorvastatin 10 mg showed no hs-CRP decrease at 1 or 6 months, whereas it significantly decreased in the 80-mg group at 6 months, but not at 1 month. In conclusion, PAPP-A significantly increased in patients with ACS compared with those with stable coronary disease. High-dose atorvastatin significantly decreased PAPP-A at 1 month and hs-CRP at 6 months in patients with verified CAD. Low-dose atorvastatin did not produce this effect.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lin T.M.
        • Galbert S.P.
        • Kiefer D.
        • Spellacy W.N.
        • Gall S.
        Characterization of four human pregnancy-associated plasma proteins.
        Am J Obstet Gynecol. 1974; 118: 223-236
        • Stulc T.
        • Malbohan I.
        • Malik J.
        • Fialova L.
        • Soukupova J.
        • Ceska R.
        Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
        Am Heart J. 2003; 146: 1060-1063
        • Aso Y.
        • Okumura K.
        • Wakabayashi S.
        • Takebayashi K.
        • Taki S.
        • Inukai T.
        Elevated pregnancy-associated plasma protein-A in sera from type 2 diabetic patients with hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index.
        J Clin Endocrinol Metab. 2004; 89: 5713-5717
        • Bayes-Genis A.
        • Conover C.
        • Overgaard M.T.
        • Bailey K.R.
        • Christiansen M.
        • Holmes Jr., D.R.
        • Virmani R.
        • Oxvig C.
        • Schwartz R.S.
        Pregnancy associated plasma protein A as a marker of acute coronary syndromes.
        N Engl J Med. 2001; 345: 1022-1029
        • Heeschen C.
        • Dimmeler S.
        • Hamm C.W.
        • Fichtlscherer S.
        • Simoons M.L.
        • Zeiher A.M.
        Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes.
        J Am Coll Cardiol. 2005; 45: 229-237
        • Lund J.
        • Qin Q.P.
        • Ilva T.
        • Pettersson K.
        • Voipio-Pulkki L.M.
        • Porela P.
        • Pulkki K.
        Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation.
        Circulation. 2003; 108: 1924-1926
        • Schwartz G.G.
        • Olsson A.G.
        • Ezekowitz M.D.
        • Ganz P.
        • Oliver M.F.
        • Waters D.
        • Zeiher A.
        • Chaitman B.R.
        • Leslie S.
        • Stern T.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Kinlay S.
        • Schwartz G.G.
        • Olsson A.G.
        • Rifai N.
        • Leslie S.J.
        • Sasiela W.J.
        • Szarek M.
        • Libby P.
        • Ganz P.
        High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL Study.
        Circulation. 2003; 108: 1560-1566
        • Dominguez-Rodriguez A.
        • Abreu-Gonzalez P.
        • Garcia-Gonzalez M.
        • Ferrer J.
        • Vargas M.
        Circulating pregnancy-associated plasma protein a is not an early marker of acute myocardial infarction.
        Clin Biochem. 2005; 38: 180-182
        • Qin Q.P.
        • Christiansen M.
        • Oxvig C.
        • Pettersson K.
        • Sottrup-Jensen L.
        • Gleich G.J.
        • Norgaard-Pedersen B.
        Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP) complex in first-trimester maternal serum screening for Down syndrome.
        Clin Chem. 1997; 43: 2323-2332
        • Qin Q.P.
        • Kokkala S.
        • Lund J.
        • Tamm N.
        • Voipio-Pulkki L.M.
        • Pettersson K.
        Molecular distinction of circulating pregnancy-associated plasma protein A in myocardial infarction and pregnancy.
        Clin Chem. 2005; 51: 75-83
        • Lund J.
        • Qin Q.P.
        • Ilva T.
        • Nikus K.
        • Eskola M.
        • Porela P.
        • Kokkala S.
        • Pulkki K.
        • Pettersson K.
        • Voipio-Pulkki L.M.
        Pregnancy associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction.
        Ann Med. 2006; 38: 221-228
        • Sangiorgi G.
        • Mauriello A.
        • Bonanno E.
        • Oxvig C.
        • Conover C.A.
        • Christiansen M.
        • Trimarchi S.
        • Rampoldi V.
        • Holmes D.R.
        • Schwartz R.S.
        • Spagnoli L.G.
        Pregnancy associated plasma protein A is markedly expressed by monocyte-macrophage cells in vulnerable and ruptured carotid atherosclerotic plaques.
        J Am Coll Cardiol. 2006; 47: 2201-2211
        • Ray K.K.
        • Cannon C.P.
        • McCabe C.H.
        • Cairns R.
        • Tonkin A.M.
        • Sacks F.M.
        • Jackson G.
        • Braunwald E.
        Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes.
        J Am Coll Cardiol. 2005; 46: 1405-1410
        • Elesber A.A.
        • Conover C.A.
        • Denktas A.E.
        • Lennon R.J.
        • Holmes Jr., D.R.
        • Overgaard M.T.
        • Christiansen M.
        • Oxvig C.
        • Lerman L.O.
        Prognostic value of circulatory pregnancy-associated plasma protein levels in patients with chronic stable angina.
        Eur Heart J. 2006; 27: 1678-1684
        • Black S.
        • Kushner I.
        • Samols D.
        C-Reactive protein.
        J Biol Chem. 2004; 279: 48487-48490
        • Bayes-Genis A.
        • Conover C.A.
        • Schwartz R.S.
        The insulin-like growth factory axis: a review of atherosclerosis and restenosis.
        Circ Res. 2000; 86: 125-130